Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cystic Fibrosis Transmembrane Conductance Regulator Activation by Roflumilast Contributes to Therapeutic Benefit in Chronic Bronchitis

9 Oct 2013

Abstract excerpt

Cigarette smoking causes acquired cystic fibrosis transmembrane conductance regulator (CFTR) dysfunction and is associated with delayed mucociliary clearance and chronic bronchitis. Roflumilast is a clinically approved phosphodiesterase 4 inhibitor that improves lung function in patients with chronic bronchitis. We hypothesized that its therapeutic benefit was related in part to activation of CFTR. Primary human...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Asthma and respiratory diseases
Share to Cystic Fibrosis Research Advances
Share to Respiratory and Cough-Related Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24106801
DOI: 10.1165/rcmb.2013-0228oc

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cystic Fibrosis Transmembrane Conductance Regulator Activation by Roflumilast Contributes to Therapeutic Benefit in Chronic BronchitisPMID 24106801Read ↗

Receptor-mediated activation of CFTR via prostaglandin signaling pathways in the airway.Semantic proximity Read ↗

Drug repurposing for Cystic Fibrosis: identification of drugs that induce CFTR-independent fluid secretion in nasal organoidsSemantic proximity Read ↗

Assessment of CFTR Dysfunction and Responsiveness to CFTR Modulators in COPD Bronchial Air‐Liquid Interface CulturesSemantic proximity Read ↗

The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease.Semantic proximity Read ↗

Mutation-independent cystic fibrosis treatment by opening calcium-activated chloride channel with a novel GPR39 agonist, DS-1039Semantic proximity Read ↗

Resveratrol and ivacaftor are additive G551D CFTR-channel potentiators: therapeutic implications for cystic fibrosis sinus disease.Semantic proximity Read ↗

CFTR Modulation Reduces SARS-CoV-2 Infection in Human Bronchial Epithelial CellsSemantic proximity Read ↗

Verapamil limits inflammation by restoring VGCC-driven epithelial Ca <sup>2+</sup> in models of cystic fibrosisSemantic proximity Read ↗

Cigarette Smoke Extract (CSE) reduces expression of functional TRPV4 channels in primary human bronchial epithelial cells differentiated at an Air Liquid Interface (ALI) in vitroSemantic proximity Read ↗

Evaluation of eluforsen, a novel RNA oligonucleotide for restoration of CFTR function in in vitro and murine models of p.Phe508del cystic fibrosisSemantic proximity Read ↗

Comparison of a novel potentiator of CFTR channel activity to ivacaftor in ameliorating mucostasis caused by cigarette smoke in primary human bronchial airway epithelial cellsSemantic proximity Read ↗

CFTR Inhibitors Display In Vitro Antiviral Activity against SARS-CoV-2Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.